ABSTRACT
Objectives The present study aimed to evaluate the efficacy of Aloe vera in the methylcellulose-induced ocular hypertension model. Methods Fifty-six rabbits were randomly divided into seven groups. Intraocular pressure (IOP) was raised by anterior chamber injection of 2% methylcellulose in all the groups except the normal control group. Disease control animals were treated with sterile water and active control with topical 0.5% timolol 12 hourly; 6 and 12% A. vera gel topical solutions 8 hourly were given in group IV and V, respectively; 6 and 12% A. vera gel solutions along with timolol were given in group VI and VII animals, respectively. Mean IOP values and percentage of reduction in IOP were compared at 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h, 36 h, and 48 h. Results A. vera gel solutions (6 and 12%) showed a significant reduction in mean IOP from 4 to 2 h time points, respectively, whereas, A. vera gel solutions (6 and 12%) + timolol showed significant less mean IOP from a 30 min time point as compared with disease control. A. vera gel solutions (6 and 12%) showed 8.6 and 10.4% more reduction in IOP, respectively (66.8 ± 4.9% and 68.6 ± 5.4% vs. 58.2 ± 2.3%; p > 0.05), whereas 6 and 12% A. vera gel solutions along with timolol showed 14.5 and 16.2% more reduction in IOP, respectively (72.7 ± 4.7% and 74.4 ± 4.1% vs. 58.2 ± 2.3%; p < 0.05), than disease control group at 48 h. Conclusions Six and twelve percent A. vera gel solutions reduced the IOP effectively. Concurrent treatment with 12% A. vera gel and timolol produced the maximum reduction in IOP.
ABSTRACT
Intravitreal triamcinolone and bevacizumab are emerging treatment modalities for the patients of macular oedema; however, they are known to raise intraocular pressure. A 61 year old diabetic male patient developed glaucoma after administration of triamcinolone acetonide and bevacizumab intravitreally for treatment of macular oedema. His intraocular pressure was raised up to about 42 mm Hg. Such high and sustained rise in intraocular pressure may lead to vision loss by damaging the optic nerve. The patient was managed by local as well as systematic therapy and was recovered after 1 month from the occurrence of an event. Intraocular pressure should be monitored in patients receiving intravitreal triamcinolone and bevacizumab. Risk benefit analysis must be done before using IVTA and IVB in patients with diabetic macular oedema.